During the nine months ended December 31, 2020, non-qualified stock options to purchase 60,000 shares were exercised at a strike price of $1.98 per share for total proceeds of $119. During the nine months ended December 31, 2019, non-qualified stock options to purchase 230,000 shares were exercised at a strike price of $1.98 per share for total proceeds of $455.

On December 30, 2020, the Company awarded restricted stock grants in the amount of 15,000 shares of its common stock to three employees. Of the 15,000 shares awarded pursuant to the restricted stock grant awards, 4,500 shares are subject to one-year vesting conditions, 4,500 shares are subject to two-year vesting conditions and 6,000 shares are subject to three-year vesting conditions.

On October 6, 2017,the Company awarded restricted stock grants totalling 3,900,000 shares of its common stock to 16 employees and awarded nonqualified stock options to purchase an aggregate of 360,000 shares of its common stock to two employees. Of the 3,900,000 shares awarded pursuant to the restricted stock grant awards, 1,200,000 shares were subject to two-year vesting conditions and 2,700,000 shares were subject to three-year vesting conditions. All of the nonqualified stock options were subject to three-year vesting conditions. On October 6, 2020, the remaining unvested restricted stock awards and nonqualified stock options from these grants made on October 6, 2017 vested to the respective grantees.

The Company recorded stock-based compensation expense for restricted stock grants and stock options in the amount of $35 and $1,090 during the three and nine months ended December 31, 2020. During the three and nine months ended December 31, 2019 the Company recorded stock-based compensation expense for restricted stock grants and stock options in the amount of $546 and $2,100, respectively.